Hypertrophic cardiomyopathy was associated with reduced quality of life (KCCQ: 88 vs 98; P<0.001) and higher societal costs (€19,035 vs €7,385/year) compared to G+/P- subjects.
Observational (n=506)
Yes
Does hypertrophic cardiomyopathy reduce quality of life and increase societal costs compared to genotype-positive phenotype-negative subjects?
Hypertrophic cardiomyopathy is associated with significantly decreased quality of life and increased societal costs compared to genotype-positive phenotype-negative individuals, particularly in younger and symptomatic patients.
Absolute Event Rate: 88% vs 98%
p-value: p=<0.001
INTRODUCTION: Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease. The impact of HCM on quality of life (QoL) and societal costs remains poorly understood. This prospective multi-centre burden of disease study estimated QoL and societal costs of genotyped HCM patients and genotype-positive phenotype-negative (G+/P-) subjects. METHODS AND RESULTS: Participants were categorized into three groups based on genotype and phenotype: (i) G+/P- left ventricular (LV) wall thickness <13 mm, (ii) non-obstructive HCM nHCM, LV outflow tract (LVOT) gradient <30 mmHg, and (iii) obstructive HCM (oHCM, LVOT gradient ≥30 mmHg). We assessed QoL with EQ-5D-5L and Kansas City Cardiomyopathy Questionnaires (KCCQ). Societal costs were measured using medical consumption (Medical Consumption Questionnaire) and productivity cost (iMTA Productivity Cost Questionnaire) questionnaires. We performed subanalyses within three age groups: <40, 40-59, and ≥60 years. From three Dutch hospitals, 506 subjects were enrolled (84 G+/P-, 313 nHCM, 109 oHCM; median age 59 years, 39% female). HCM (both nHCM and oHCM) patients reported reduced QoL vs. G+/P- subjects (KCCQ: 88 vs. 98, EQ-5D-5L: 0.88 vs. 0.96; both P < 0.001). oHCM patients reported lower KCCQ scores than nHCM patients (83 vs. 89, P = 0.036). Societal costs were significantly higher in HCM patients (€19,035/year vs. €7385/year) compared with G+/P- controls, mainly explained by higher healthcare costs and productivity losses. Being symptomatic and of younger age (<60 years) particularly led to decreased QoL and increased costs. CONCLUSION: HCM is associated with decreased QoL and increased societal costs, especially in younger and symptomatic patients. oHCM patients were more frequently symptomatic than nHCM patients. This study highlights the substantial disease burden of HCM and can aid in assessing new therapy cost-effectiveness for HCM in the future.
Schoonvelde et al. (Fri,) conducted a observational in Hypertrophic cardiomyopathy (n=506). Hypertrophic cardiomyopathy (HCM) vs. Genotype-positive phenotype-negative (G+/P-) subjects was evaluated on Quality of life (KCCQ score) (p=<0.001). Hypertrophic cardiomyopathy was associated with reduced quality of life (KCCQ: 88 vs 98; P<0.001) and higher societal costs (€19,035 vs €7,385/year) compared to G+/P- subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: